Suppr超能文献

中国内地胸主动脉腔内修复术治疗 B 型主动脉夹层的结局评估。

The Evaluation of Outcomes after Thoracic Endovascular Aortic Repair for Type B Aortic Dissection in Mainland China.

机构信息

Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, China; Department of Emergency Surgery, The People's Hospital of Peking University, Beijing, China.

Department of Vascular and Endovascular Surgery, Chinese PLA General Hospital, Beijing, China.

出版信息

Ann Vasc Surg. 2024 Jul;104:217-226. doi: 10.1016/j.avsg.2023.12.087. Epub 2024 Mar 18.

Abstract

BACKGROUND

To assess the mortality and outcomes after thoracic endovascular aortic repair (TEVAR) in patients with type B aortic dissection (TBAD) in mainland China, and to compare these outcomes with data from Western countries, while analyzing the potential reasons for differences among different countries.

METHODS

An extensive literature search spanning from January 1999 to October 2023 was conducted using PubMed, Cochrane Library, and Embase databases for studies on endovascular treatment for TBAD. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Data extraction and analysis followed the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Primary outcomes were in-hospital mortality and mid-term (< 5 years) mortality.

RESULTS

Based on 25 publications (3,080 patients), pooled estimate for in-hospital mortality was 2.2% (95% confidence interval, 1.6%-2.9%). Major perioperative complications included stroke (2.4% [1.8%-3.3%]), spinal cord ischemia (1.4% [1.0%-2.2%]), retrograde type A aortic dissection (1.2% [0.8%-1.8%]), type I endoleak (5.6% [3.6%-8.6%]), visceral ischemia (1.0% [0.5%-2.1%]), and acute renal failure (2.8% [2.0%-3.8%]). Mid-term mortality was 5.1% (3.6%-7.3%), and secondary intervention rate was 4.9% (4.0%-6.0%) with 1.7% (1.0%-2.9%) conversion rate to open surgery. In subgroup analysis based on uncomplicated TBAD, in-hospital and mid-term mortality was 0.5% (0.2%-1.5%) and 0.6% (0.2-1.7%), respectively. Compared with data from Western countries, mainland Chinese patients had a lower mortality.

CONCLUSIONS

In mainland China, the outcomes of endovascular treatment for TBAD are comparable to those of Western countries. The large number of patients undergoing TEVAR in mainland China and its good performance support the use of TEVAR in uncomplicated TBAD.

摘要

背景

评估中国大陆地区胸主动脉腔内修复术(TEVAR)治疗 B 型主动脉夹层(TBAD)患者的死亡率和预后,并与西方国家的数据进行比较,同时分析不同国家之间差异的潜在原因。

方法

从 1999 年 1 月至 2023 年 10 月,通过 PubMed、Cochrane 图书馆和 Embase 数据库广泛检索关于 TEVAR 治疗 TBAD 的文献,进行系统回顾和荟萃分析。本研究遵循系统评价和荟萃分析的首选报告项目声明。数据提取和分析遵循系统评价和荟萃分析的首选报告项目声明中的指南。主要结局指标为住院死亡率和中期(<5 年)死亡率。

结果

基于 25 项研究(3080 例患者),汇总估计住院死亡率为 2.2%(95%置信区间,1.6%-2.9%)。主要围手术期并发症包括卒中(2.4%[1.8%-3.3%])、脊髓缺血(1.4%[1.0%-2.2%])、逆行性 A 型主动脉夹层(1.2%[0.8%-1.8%])、Ⅰ型内漏(5.6%[3.6%-8.6%])、内脏缺血(1.0%[0.5%-2.1%])和急性肾衰竭(2.8%[2.0%-3.8%])。中期死亡率为 5.1%(3.6%-7.3%),二次干预率为 4.9%(4.0%-6.0%),转化率为 1.7%(1.0%-2.9%)至开放手术。基于单纯 TBAD 的亚组分析,住院死亡率和中期死亡率分别为 0.5%(0.2%-1.5%)和 0.6%(0.2-1.7%)。与西方国家的数据相比,中国大陆地区患者的死亡率较低。

结论

在中国大陆地区,TEVAR 治疗 TBAD 的结局与西方国家相当。中国大陆地区接受 TEVAR 治疗的患者数量较多,且表现良好,支持在单纯 TBAD 中使用 TEVAR。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验